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Matrix metalloproteases (MMPs) have been implicated in a number of different human diseases and are
currently one of the actively pursued targets in drug discovery and development. In this issue of Structure,
Udi and colleagues describe how an inhibitory antibody, LEM-2/15, affects a member of the MMP family,
MT1-MMP.Matrix metalloproteases (MMPs) play a
pivotal role in tissue remodeling by virtue
of their unique ability to degrade macro-
molecules of extracellular matrix (ECM).
The activity of these enzymes is inexo-
rably linked to the control of ECM re-
structuring during morphogenesis, tissue
repair, angiogenesis, uterine involution,
and bone resorption. MMPs have been
implicated in various pathological condi-
tions including arthritis and inflammatory
diseases. Malignant cells exploit MMPs
to promote tumor invasion and metas-
tasis. Hence, in the recent past, MMPs
were considered to be rich targets for
drug development. Understandably, a
great deal of effort was devoted to pro-
duce small molecule inhibitors targeting
the active site (Hopkins and Groom,
2002). However, development of effective
therapeutics based on this strategy re-
mains an elusive goal to a large extentFigure 1. Binding of LEM-2/15 Antibody to MT1-MMP Induces
Conformational Perturbation, Leading to Narrowing of the Substrate
Binding Cleft
(Left) MT1-MMP is shown residing attached to the cell surface and engaged
with the substrate. (Right) Binding of LEM-2/15 antibody to the allosteric site
inhibits substrate binding and thus the activity of MT1-MMP.because of the high structural
homology at the active site
shared by proteases of this
family (Hopkins and Groom,
2002, Overall and Lo´pez-
Otı´n, 2002; Sela-Passwell
et al., 2010a). Moreover, the
first generation of MMP inhib-
itors failed in clinical trials
because of unspecific inhibi-
tion of other processes that
the MMPs are involved in
in vivo (Lo´pez-Otı´n et al.,
2009; Overall and Kleifeld,
2006). Targeting specific
inhibitory sites residing
outside the conserved cata-
lytic cleft was suggested as
an alternative drug design
approach to control MMPs’
activity in vivo (Sela-Passwell
et al., 2010b). Recently, the
pursuit of selective MMP in-6 Structure 23, January 6, 2015 ª2015 Elsevihibitors has begun to shift toward select-
ing monoclonal antibodies targeting exo-
sites and allosteric interactions of the
specific enzymes.
Thus far, several inhibiting antibodies
against MMPs have been reported in the
literature. However, information regarding
the inhibitionmechanism is still somewhat
limited. For example, REGA-3G12, a high-
ly selective MMP-9 inhibitor that binds
with high affinity (Hu et al., 2004; Martens
et al., 2007) recognizes the N-terminal
part of the catalytic domain of MMP-9
and does not bind the catalytic zinc ion
(Martens et al., 2007). Moreover, Dyax
recently developed a potent and highly
selective membrane type 1 (MT1)-MMP
antibody, DX-2400 (Devy et al., 2009).
This antibody inhibits MT1-MMP in a
competitive manner, implying direct inter-
action with the zinc ion or blockage of
the catalytic cleft. In addition, anotherer Ltd All rights reservedanti-MT1-MMP antibody, termed 9E8,
has been reported recently (Ingvarsen
et al., 2013; Shiryaev et al., 2013). This
antibody inhibits an MT1-MMP depen-
dent MMP-2 activation while maintaining
other functions, and yet the molecular
details remain to be clarified. Intriguingly,
Sela-Passwell et al. (2012) recently
reported an antibody that inhibits the
catalytic activity of MMP-2/9 by direct
interaction with the catalytic zinc ion.
These reports suggest that the mecha-
nisms by which antibodies can inhibit
proteases include either direct binding at
the catalytic cleft or indirect inhibition by
binding to allosteric regions.
In this issue of Structure, Udi et al.
(2015) present a detailed molecular and
biophysical description of the interaction
between MT1-MMP with an inhibitory
antibody, LEM-2/15. This antibody was
generated against an exposed surfaceloop of MT1-MMP (residues
218–233, the V-B loop) (Ga´l-
vez et al., 2001). Kinetic and
binding studies confirmed
that LEM-2/15 is a highly
selective potent MT1-MMP
inhibitor, affecting mainly the
collagenolytic activity of
MT1-MMP in biological as-
says. LEM-2/15 inhibits the
enzymatic activity of MT1-
MMP against a small syn-
thetic peptide as well as
against native substrates,
collagen type I, and gelatin.
Here, protein crystallog-
raphy sheds light on the mo-
lecular mechanism of the allo-
steric inhibition of MT1-MMP.
Interaction of the enzyme
with LEM-2/15 induces con-
formational changes so that
the V-B loop of MT1-MMP
Structure
Previews‘‘flips out’’ toward the antibody, resulting
in narrowing of the substrate-binding
cleft (Figure 1). The narrowing of the
substrate binding cleft between the V-B
loop and the region of the active site
involved in substrate binding, S1’, along
with likely imposed constrains on the
loop flexibility explain the basis of the
allosteric inhibition by the LEM-2/15
antibody.
Most impressive is the fact that the
antibody reduced cell surface collageno-
lytic activity in a fibrosarcoma cell line
having little effect on the enzyme dimer-
ization or on MT1-MMP-dependent acti-
vation of MMP-2. This work marks the
progress toward identification of the
enzyme specific surface exposed epi-
topes that are important for the control
of enzymatic activity and can provide
an entree into development of novel
therapeuticsREFERENCES
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In this issue of Structure, Glatt and colleagues report the structure of the Kti11/Kti13 heterodimer. This study
reveals how dimerization and Fe2+ binding are required for modification of both tRNA and EF2, thus suggest-
ing a mechanism for regulation of translation elongation via two different pathways.The amount of proteins synthesized in a
cell must be tuned in response to chang-
ing environmental and developmental
conditions. While regulation of gene
expression at the transcriptional level
has been described for decades, the
importance of translational control in
cellular responses has more recently
also been recognized, and an increasing
number of subtle mechanisms to regu-
late translation elongation have been
discovered.
Translation elongation factor 2 (EF2)
occupies an essential role in protein
translation, where it catalyzes the translo-
cation of the ribosome along the mRNA.
EF2 contains a diphtamide modificationon a conserved histidine residue, which
interacts with the ribosomal decoding
center (Schaffrath et al., 2014). In eukary-
otes, addition of this modification occurs
via a four-step pathway involving the pro-
teins Dph1–Dph7. The first step in this
pathway is catalyzed by the [4Fe-4S] clus-
ter-containing heterodimeric protein
complex Dph1/Dph2, with the help of
Dph3 and Dph4. Although the diphtamide
group of EF2 is the target for ADP-ribosy-
lation by the bacterial diphtheria toxin, its
exact physiological role is not yet fully un-
derstood. Recently, it has been sug-
gested that cells have an in-built capacity
to ADP-ribosylate the diphtamide group
and that this activity is increased undercertain cellular stresses, leading to a
global decrease of protein translation at
the expense of an upregulation of IRES-
dependent translation of mRNAs impli-
cated in oxidative stress protection
(Argu¨elles et al., 2014) (Figure 1).
Codon bias in certain subsets of
genes, coupled to regulation of specific
tRNA modifications, forms another strat-
egy to regulate translation elongation.
Chemical modifications at the wobble
position of tRNA play an important role
in translation rate and accuracy by
stabilizing codon-anticodon interactions
in the A site of the ribosome. Accord-
ingly, it has become increasingly
apparent recently that tRNA wobble15 ª2015 Elsevier Ltd All rights reserved 7
